

.....  
(Original Signature of Member)

116TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and  
for other purposes.

\_\_\_\_\_  
IN THE HOUSE OF REPRESENTATIVES

Ms. MATSUI introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To reauthorize the Stem Cell Therapeutic and Research Act  
of 2005, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Timely ReAuthoriza-  
5 tion of Necessary Stem-cell Programs Lends Access to  
6 Needed Therapies Act of 2019” or the “TRANSPLANT  
7 Act of 2019”.

1 **SEC. 2. REAUTHORIZATION OF THE C. W. BILL YOUNG CELL**  
2 **TRANSPLANTATION PROGRAM.**

3 (a) **ADVISORY COUNCIL MEETINGS.**—Subsection (a)  
4 of section 379 of the Public Health Service Act (42 U.S.C.  
5 274k) is amended by adding at the end the following new  
6 paragraph:

7 “(7) The Secretary shall convene the Advisory  
8 Council at least two times each calendar year.”.

9 (b) **INCREASING COLLECTION.**—

10 (1) **TECHNICAL CLARIFICATION.**—Effective as  
11 if included in the enactment of Public Law 114–104  
12 (the Stem Cell Therapeutic and Research Reauthor-  
13 ization Act of 2015), the amendment to section  
14 379(d)(2)(B) of the Public Health Service Act (42  
15 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public  
16 Law 114–104 is amended by inserting “goal of in-  
17 creasing collections of high quality” before “cord  
18 blood units,”.

19 (2) **ELIMINATING DEADWOOD.**—Subparagraph  
20 (B) of section 379(d)(2) of the Public Health Serv-  
21 ice Act (42 U.S.C. 274k(d)(2)) is amended by strik-  
22 ing the second and third sentences in such subpara-  
23 graph.

24 (c) **PERIODIC REVIEW OF STATE OF SCIENCE.**—Sec-  
25 tion 379 of the Public Health Service Act (42 U.S.C.

1 274k) is amended by adding at the end the following new  
2 subsection:

3 “(o) PERIODIC REVIEW OF STATE OF SCIENCE.—

4 “(1) REVIEW.—Not less than every two years,  
5 the Secretary, in consultation with the Director of  
6 the National Institutes of Health, the Commissioner  
7 of Food and Drugs, the Administrator of the Health  
8 Resources and Services Administration, the Advisory  
9 Council, and other stakeholders, where appropriate  
10 given relevant expertise, shall conduct a review of  
11 the state of the science of using adult stem cells and  
12 birthing tissues to develop new types of therapies for  
13 patients, for the purpose of considering the potential  
14 inclusion of such new types of therapies in the Pro-  
15 gram.

16 “(2) RECOMMENDATIONS.—Not later than  
17 June 30, 2024, the Secretary shall—

18 “(A) complete the second review required  
19 by paragraph (1); and

20 “(B) informed by such review, submit to  
21 the Committee on Health, Education, Labor,  
22 and Pensions of the Senate and the Committee  
23 on Energy and Commerce of the House of Rep-  
24 resentatives recommendations on the appro-

1           priateness of the inclusion of new types of  
2           therapies in the Program.”.

3           (d) AUTHORIZATION OF APPROPRIATIONS.—Section  
4 379B of the Public Health Service Act (42 U.S.C. 274m)  
5 is amended by striking “\$33,000,000 for fiscal year 2015  
6 and \$30,000,000 for each of fiscal years 2016 through  
7 2020” and inserting “\$30,000,000 for each of fiscal years  
8 2021 through 2025”.

9   **SEC. 3. CORD BLOOD INVENTORY.**

10          Subsection (g) of section 2 of the Stem Cell Thera-  
11 peutic and Research Act of 2005 (42 U.S.C. 274k note)  
12 is amended to read as follows:

13          “(g) AUTHORIZATION OF APPROPRIATIONS.—To  
14 carry out this section, there is authorized to be appro-  
15 priated \$23,000,000 for each of fiscal years 2021 through  
16 2025.”.